Advanced Renal Cell Carcinoma Treatment Market Size

  • Report ID: 3895
  • Published Date: Jul 26, 2024
  • Report Format: PDF, PPT

Advanced Renal Cell Carcinoma Treatment Market Size

Advanced Renal Cell Carcinoma Treatment Market size was valued at USD 6.34 Billion in 2023 and is set to reach USD 13.04 Billion by the end of 2036, registering around 5.7% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of advanced renal cell carcinoma treatment is assessed at USD 6.67 Billion. The growth of the market can be attributed to the increasing cases of renal cancer amongst the population across the globe. A family history of renal cancer is the biggest cause of the such type of cancer. For instance, renal cell carcinoma (RCC) is a dangerous neoplasm that accounts for around 5% of worldwide cancer diagnoses and fatalities, and its global burden is expected to radically rise in the coming years. Moreover, high blood pressure, along with excessive smoking, and the increasing awareness amongst the people regarding early diagnosis and treatment of cancer, is estimated to boost the global advanced renal cell carcinoma treatment market growth over the forecast period.

In addition to these, factors that are believed to fuel the market growth of advanced renal cell carcinoma treatment include the rise in inactive and sedentary lifestyles throughout the world. As per the World Health Organization (WHO) report, physical inactivity is responsible for around 2 million deaths worldwide each year. Sedentary lifestyles are practiced by 60 to 85% of people worldwide, including both developed and developing countries, making it one of the most severe yet under-addressed public health issues of the present time. In addition to this, a surge in the availability of novel drugs and treatments is the major factor that is projected to spur market growth during the forecast period.


Advanced-Renal-Cell-Carcinoma-Treatment-Market-scope
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3895
  • Published Date: Jul 26, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of advanced renal cell carcinoma treatment is assessed at USD 6.67 Billion.

The advanced renal cell carcinoma treatment market size was valued at USD 6.34 Billion in 2023 and is set to reach USD 13.04 Billion by the end of 2036, registering around 5.7% CAGR during the forecast period i.e., between 2024-2036. Growing proportion of geriatric population, worldwide increasing ratio of smoking, and an upsurge in hypertension are the major factors driving the market growth.

North America is projected to dominate majority industry share by 2036, attributed to increasing prevalence of renal cell carcinoma and other cancers in the region.

Ono Pharmaceutical Co., Ltd., Novartis AG, Merck & Co., Inc., Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Bayer AG, Pfizer Inc., AbbVie Inc., Teva Pharmaceuticals Industries Ltd.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying